Bioarray Therapeutics Inc.

Description

• BIOARRAY genetics is a biotech company located in New Haven CT developing and commercializing molecular tests in the oncology space. Despite a broad range of breast cancer molecular tests on the market today, there is a gap in the testing regimen resulting in a trial and error approach to treatment. Presently, approximately 75% of the 155,000 breast cancer patients who undergo the standard-of-care chemotherapy do not completely respond to the treatment, costing the U.S healthcare system $2.59 billion annually. The additional costs include patient morbidity and wasted time to efficacious treatment.The company's first test is a RNA-based predictive test (BA100) that is able to identify breast cancer patients who will and will not realize a complete response to the traditional pre-surgery chemotherapy, resulting in over 50% reduction in wasted treatments. By properly identifying those patients that will not respond to the first-line chemotherapy treatment, BIOARRAYs predictive test enables physicians to optimize treatments and potentially save the healthcare system $1.4 billion annually in the U.S. There are presently no tests available that provide the vital information generated by BIOARRAYs lead predictive test which has a market opportunity of over $540 million annually in the U.S. alone. BIOARRAY's proprietary platform, consisting of a gene expression assay for a panel of over 300 unique genes coupled with proprietary algorithms, is the foundation for the development of predictive tests for cancer treatments, as well as a template for companion diagnostics.
• 

  Headquarters:400 Farmington Avenue , Farmington, Connecticut, United States

  More
• 

  Phone Number:

• 

  Website: https://www.bioarray.us

• 

  Employees:6

• 

  Revenue:$1 - 10M

• 

  Legal Name:Bioarray Therapeutics Inc.

• Bioarray Therapeutics Inc.'s Social Media

  
• Is this data correct?

• |  NAICS Code: 541713  |

  Show More